Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA – Yahoo Finance
|
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
Yahoo Finance PA) (CYAD), a leader in the discovery and development of engineered cell-based therapies, today announced that the U.S. FDA authorized the initiation of the THINK trial in the U.S. THINK evaluates NKR-2 CAR–T cells in seven indications, five solid … |
